Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.

@article{Burgess2005AssessmentOT,
  title={Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.},
  author={Cheryl M. Burgess and Rafaela M. Quiroga},
  journal={Journal of the American Academy of Dermatology},
  year={2005},
  volume={52 2},
  pages={
          233-9
        }
}
BACKGROUND Lipodystrophy syndrome is uniquely associated with the use of highly active antiretroviral therapy (HAART) containing protease inhibitors or nucleoside reverse transcriptase inhibitors. Between 15% and 80% of patients on HAART develop facial lipoatrophy within 10 months of initiating therapy. At present, no ideal treatment strategies have emerged in spite of the psychosocial stress, resulting in depression and isolation in many HIV-infected patients. Most soft tissue fillers seem to… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 54 CITATIONS

FILTER CITATIONS BY YEAR

2006
2017

CITATION STATISTICS

  • 2 Highly Influenced Citations

  • Averaged 1 Citations per year over the last 3 years

Similar Papers

Loading similar papers…